دورية أكاديمية
An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.
| العنوان: | An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC. |
|---|---|
| المؤلفون: | Wang H; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China. Electronic address: wanghui19901118@outlook.com., Hu L; Department of Thoracic Oncology, the Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China., Zhang F; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China., Fang M; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China., Xu J; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China., Li M; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China., Chen Z; Department of Radiation Oncology, Xiaolan People's Hospital of Zhongshan (The Fifth People's Hospital of ZhongShan), No. 65, Jucheng Rd. Xiaolan Dist. 528415, Zhongshan, Guangdong Prov., China. |
| المصدر: | Oral oncology [Oral Oncol] 2024 Jun; Vol. 153, pp. 106814. Date of Electronic Publication: 2024 May 06. |
| نوع المنشور: | Journal Article; Meta-Analysis; Systematic Review; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam : Elsevier Original Publication: Oxford ; New York : Pergamon, c1997- |
| مواضيع طبية MeSH: | Vascular Endothelial Growth Factor A*/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor*/antagonists & inhibitors , Squamous Cell Carcinoma of Head and Neck*/drug therapy, Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Head and Neck Neoplasms/drug therapy ; Male ; Female |
| مستخلص: | Objectives: Exploration into the use of vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) inhibitors alongside programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has been undertaken for treating recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). We conducted a meta-analysis to provide a more precise assessment of the efficacy and safety of this integrated approach in managing R/M HNSCC. Methods: A systematic exploration encompassing PubMed, Embase, the Cochrane Library, and Web of Science databases was undertaken to figure out relevant studies. It was attempted to analyze critical endpoints, such as overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) utilizing a random-effects model. Results: Eleven studies, encompassing 413 patients, were analyzed. The combined data revealed an ORR of 41 % (95 % CI: 34-49 %), a DCR of 67 % (95 % CI: 51-83 %), a median PFS of 5.87 months (95 % CI: 3.90-7.85), and a median OS of 9.63 months (95 % CI: 6.78-12.49). Furthermore, the rates for 1-year PFS and OS were 45 % (95 % CI: 27-64 %) and 65 % (95 % CI: 49-81 %), respectively. The occurrence of grade 3 or higher adverse events related to the drugs was 20 % (95 % CI: 10-30 %). Subgroup analysis within the tyrosine kinase inhibitor (TKI) group revealed an ORR of 47 % (95 % CI: 39 %-55 %) and a DCR of 67 % (95 % CI: 46 %-88 %). Conclusions: In summary, combining VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors shows considerable effectiveness with manageable side effects in cases with R/M HNSCC. Systematic Review Registration: Registered with the International Prospective Register of Systematic Reviews, identifier CRD42023486345. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Head and neck squamous cell carcinoma; Immune checkpoint inhibitors; Meta-analysis; Metastatic; Recurrent; Vascular endothelial growth factor |
| المشرفين على المادة: | 0 (CD274 protein, human) 0 (PDCD1 protein, human) 0 (VEGFA protein, human) |
| تواريخ الأحداث: | Date Created: 20240507 Date Completed: 20240519 Latest Revision: 20240620 |
| رمز التحديث: | 20240620 |
| DOI: | 10.1016/j.oraloncology.2024.106814 |
| PMID: | 38714115 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1879-0593 |
|---|---|
| DOI: | 10.1016/j.oraloncology.2024.106814 |